The RSV vaccine is recommended for:
- Pregnant women during the third trimester (from week 28 onward) to protect their babies by antibody transfer.
- Infants under 6 months of age can receive a monoclonal antibody injection at birth or before discharge.
- All adults aged 75 years and older.
- Adults aged 50-74 years who have risk factors for severe RSV disease, such as chronic heart or lung disease, weakened immune system, diabetes with organ damage, neurological or neuromuscular conditions, residents of long-term care facilities, or medically frail individuals.
The recommended timing for vaccination in adults is before the RSV season, generally late summer or early fall. Pregnant women should get the vaccine between weeks 32-36 of pregnancy if that overlaps with RSV season. The vaccine is currently a single dose and is not recommended annually as protection lasts more than a year. These recommendations are based on WHO, CDC, UK, Canada, and other health authority guidance for 2025 RSV vaccine use.
